Crossmark

Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence

Crossref DOI link: https://doi.org/10.1007/s40261-018-0705-6

Published Online: 2018-09-28

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nazha, Sara https://orcid.org/0000-0002-8135-0197
Tanguay, Simon

Kapoor, Anil

Jewett, Michael

Kollmannsberger, Christian

Wood, Lori

Bjarnason, G. A. Georg

Heng, Daniel

Soulières, Denis

Reaume, Martin Neil

Basappa, Naveen

Lévesque, Eric

Dragomir, Alice
Funding

Funding for this research was provided by:

Fonds de Recherche du Québec - Santé

Canadian Centre for Applied Research in Cancer Control.

Coté-Sharp Family Foundation
License Information

Text and Data Mining valid from 2018-09-28
More Information

Article History

First Online: 28 September 2018

Compliance with Ethical Standards

:

: The project was approved by the Research Ethics Board of each individual participating centers and all patients provided consent for entry into CKCis.

: Sara Nazha received a scholarship award from the Canadian Center for Applied Research in Cancer Control. Dr. Dragomir obtained salary support from the Coté-Sharp Family Foundation at the McGill University Health Center. Since June 2016, she is a Fonds de Recherche du Québec—Santé (FRQS) Junior 1 Research Scholar.

: No authors have any competing interests to declare.